CA-SIRIUS-THERAPEUTICS
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.
“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”
The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.
About Thromboembolic Disorders
Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.
About SRSD107
SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.
About Sirius Therapeutics
Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.
[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO wins prestigious German Sustainability Award 20269.12.2025 09:07:00 CET | Press release
INNIO Group has been awarded the German Sustainability Award for Companies 2026. At the 18th annual ceremony in Düsseldorf, INNIO was named winner in the “Engines and Turbines” category within the “Machines and Installations” sector. Recognized as one of Europe’s most respected distinctions for corporate responsibility, the German Sustainability Award reflects the United Nations’ Agenda 2030 and thus on the key areas of transformation such as climate, biodiversity, resources, supply chain, and society. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205520809/en/ INNIO wins prestigious German Sustainability Award 2026 (c) Frank Fendler “This award is a tremendous recognition for our entire team and validates our 360-degree approach to sustainable innovation throughout the value chain,” said Marcin Kawa, VP Sustainability at INNIO Group. “We are committed to actively shaping the energy transition and delivering solutions th
EURONICS and NIQ Forge Strategic Collaboration to Elevate Retail Pricing Intelligence9.12.2025 09:00:00 CET | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company combined with GfK in 2023, has been selected by EURONICS, a leading global shopping cooperative in the Technical Consumer Goods (TCG) sector, to provide comprehensive Online Price Monitoring. NIQ's Online Price Monitoring provides insights into pricing dynamics by tracking item-level pricing across a defined data set. The system captures product information, matches items accurately, and ensures quality through advanced automated processes combined with human oversight and detailed checks. NIQ offers a range of retail pricing solutions, including pricing intelligence tools and the Consumer Price Lab, empowering businesses to make informed decisions and optimize their pricing strategies. This collaboration focuses on providing EURONICS with comprehensive pricing insights to support informed decision-making. NIQ delivers accurate and transparent data to help EURONICS understand market dynamics and plan effectively. "Through our col
SonicEdge and Earfab Partner to Shape the Future of Personalized Audio and Hearing Wellness9.12.2025 09:00:00 CET | Press release
Partnership unites SonicEdge’s micro-speaker technology with Earfab’s custom-fit innovation to deliver unmatched comfort and fidelity SonicEdge, a pioneer in micro-acoustic innovation, today announced a strategic partnership with Earfab, the innovator of custom-fit hearing technology, to co-develop a new generation of personalized audio solutions that unite comfort, precision, and hearing safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209472421/en/ Credit: SonicEdge By combining SonicEdge’s high-performance MEMS speaker-in-chip technology with Earfab’s custom-fit eartips – crafted using its proprietary earfabSCAN 3D smartphone scanning platform – the collaboration delivers a first-of-its-kind experience that redefines in-ear performance. The joint solution provides a perfect acoustic seal for enhanced sound fidelity, improved active noise cancellation, and long-term listening comfort – without compromising hearing
Outpost24 Acquires Infinipoint to Power Its Entry into the Zero Trust Workforce Access Market9.12.2025 08:00:00 CET | Press release
The strategic acquisition strengthens market leadership by unifying user identity with device trust, eliminating security blind spots. Outpost24, a leader in exposure management and identity security, today announced the acquisition of Infinipoint, a specialist in device identity, posture validation, and secure workforce access. The acquisition marks Outpost24’s entry into the Zero Trust Workforce Access market and enhances its identity security division, Specops, by laying the foundation for a unified approach that evaluates both the user and the device before access is granted. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208750630/en/ Ido Erlichman, Chief Executive Officer of Outpost24. As organizations advance their Zero Trust strategies, authentication alone is no longer enough. MFA and SSO confirm who the user is, but they do not validate the security of the device being used. In hybrid environments where employee
VSO Submits VCP v1.0 to Nineteen Regulatory Authorities Across Thirteen Jurisdictions and Completes First Integrated Evaluation in a Production-Like Environment9.12.2025 08:00:00 CET | Press release
The VeritasChain Standards Organization (VSO) announced today that it has submitted the VeritasChain Protocol (VCP) v1.0 to nineteen regulatory authorities across thirteen jurisdictions, including the United States, United Kingdom, European Union, Singapore, Hong Kong, United Arab Emirates (DIFC), Australia, India, South Korea, Switzerland, Brazil, Liechtenstein, and Saudi Arabia. The submissions present VCP v1.0 as a cryptographic audit framework designed to address emerging supervisory requirements under the EU AI Act Article 12 for logging and traceability, and MiFID II / RTS 25 for timestamp integrity and event ordering in AI-driven and algorithmic trading systems. VSO also confirmed the first completed integration of VCP v1.0 within a controlled, production-like evaluation environment operating under its Early Access Program. The environment successfully generated cryptographically linked event chains, immutable hashing, and verifiable proofs using RFC-aligned structures, demonstr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom